Ontology highlight
ABSTRACT: Background
The aim of this study was to prospectively screen patients with a positive family history of carcinoid small intestine neuroendocrine tumors (SI-NETs) to elucidate the benefits of early detection and operative intervention.Methods
A single-center, prospective trial was conducted from 2008 to 2014 that evaluated patients with 2 or more blood relatives with carcinoid SI-NETs. All eligible patients were screened with urine/serum biochemistries and various imaging modalities. Operative intervention was elected in patients found to have at least 1 positive diagnostic study.Results
Twenty-nine patients from 13 families had occult carcinoid SI-NETs (15 female, 14 male). Twenty-four of the 29 patients (83%) had multifocal disease found in either the distal jejunum or ileum. On average, 75.9 cm (range, 13-195) of bowel was resected in 1 segment. Three patients were found to have stage IV disease at operation. All stage I-IIIB patients who had R0 resections have remained disease-free, with a median follow-up of 35 months.Conclusion
Familial carcinoid SI-NETs often are asymptomatic and can be diagnosed with aggressive screening. With early detection, there may be a window of opportunity for operative resection to change the natural history of this disease and even prove to be curative.
SUBMITTER: Hughes MS
PROVIDER: S-EPMC4858646 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
Hughes Marybeth S MS Azoury Saïd C SC Assadipour Yasmine Y Straughan David M DM Trivedi Apurva N AN Lim Ramona M RM Joy Grishma G Voellinger Mark T MT Tang Derek M DM Venkatesan Aradhana M AM Chen Clara C CC Louie Adeline A Quezado Martha M MM Forbes Joanne J Wank Stephen A SA
Surgery 20151009 1
<h4>Background</h4>The aim of this study was to prospectively screen patients with a positive family history of carcinoid small intestine neuroendocrine tumors (SI-NETs) to elucidate the benefits of early detection and operative intervention.<h4>Methods</h4>A single-center, prospective trial was conducted from 2008 to 2014 that evaluated patients with 2 or more blood relatives with carcinoid SI-NETs. All eligible patients were screened with urine/serum biochemistries and various imaging modaliti ...[more]